DynaCirc CR

DynaCirc CR is a brand name of isradipine, approved by the FDA in the following formulation(s):

DYNACIRC CR (isradipine - tablet, extended release; oral)

• 
  Manufacturer: GLAXOSMITHKLINE LLC
  
  Approval date: June 1, 1994
  
  Strength(s): 10MG ^[RLD], 5MG
  

Has a generic version of DynaCirc CR been approved?

No. There is currently no therapeutically equivalent version of DynaCirc CR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DynaCirc CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with DynaCirc CR.

See also...

• DynaCirc CR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Dynacirc CR Consumer Information (Cerner Multum)
• Dynacirc CR Advanced Consumer Information (Micromedex)
• Isradipine Consumer Information (Wolters Kluwer)
• Isradipine Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Isradipine Consumer Information (Cerner Multum)
• Isradipine Advanced Consumer Information (Micromedex)
• Isradipine AHFS DI Monographs (ASHP)

Ponsolit

Ponsolit may be available in the countries listed below.

Ingredient matches for Ponsolit

Tenoxicam

Tenoxicam is reported as an ingredient of Ponsolit in the following countries:

• Greece

International Drug Name Search

Sodium Sulamyd

In the US, Sodium Sulamyd (sulfacetamide sodium ophthalmic) is a member of the drug class ophthalmic anti-infectives and is used to treat Conjunctivitis and Trachoma.

US matches:

• Sodium Sulamyd

Ingredient matches for Sodium Sulamyd

Sulfacetamide Sodium

Sulfacetamide sodium salt (a derivative of Sulfacetamide) is reported as an ingredient of Sodium Sulamyd in the following countries:

• Canada

International Drug Name Search

Clotrimin

Clotrimin may be available in the countries listed below.

Ingredient matches for Clotrimin

Clotrimazole

Clotrimazole is reported as an ingredient of Clotrimin in the following countries:

• Chile

International Drug Name Search

Humacarpin

Humacarpin may be available in the countries listed below.

Ingredient matches for Humacarpin

Pilocarpine

Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Humacarpin in the following countries:

• Hungary

International Drug Name Search

Dopagyt

Dopagyt may be available in the countries listed below.

Ingredient matches for Dopagyt

Methyldopa

Methyldopa is reported as an ingredient of Dopagyt in the following countries:

• India

International Drug Name Search

DexOptifen

DexOptifen may be available in the countries listed below.

Ingredient matches for DexOptifen

Dexibuprofen

Dexibuprofen is reported as an ingredient of DexOptifen in the following countries:

• Latvia


• Lithuania


• Switzerland

International Drug Name Search

Zmax

Zmax is a brand name of azithromycin, approved by the FDA in the following formulation(s):

ZMAX (azithromycin - for suspension, extended release; oral)

• 
  Manufacturer: PFIZER GLOBAL
  
  Approval date: June 10, 2005
  
  Strength(s): EQ 2GM BASE/BOT ^[RLD]

Has a generic version of Zmax been approved?

No. There is currently no therapeutically equivalent version of Zmax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zmax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled-release dosage forms of Azithromycin
  Patent 6,068,859
  Issued: May 30, 2000
  Inventor(s): Curatolo; William J. & Friedman; Hylar L. & Korsmeyer; Richard W. & LeMott; Steven R.
  Assignee(s): Pfizer Inc.
  A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
  
  Patent expiration dates:
  
  
  • May 30, 2017
    
    ✓ 
    Drug product
  
  



• 
  Azithromycin dihydrate
  Patent 6,268,489
  Issued: July 31, 2001
  Inventor(s): Allen; Douglas J. M. & Nepveux; Kevin M.
  Assignee(s): Pfizer Inc.
  Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.
  
  Patent expiration dates:
  
  
  • July 31, 2018
    
    ✓ 
    Drug substance
  
  



• 
  Azithromycin dosage forms with reduced side effects
  Patent 6,984,403
  Issued: January 10, 2006
  Inventor(s): Hagen; Timothy A. & Lo; Julian B. & Thombre; Avinash G. & Herbig; Scott M. & Appel; Leah Elizabeth & Crew; Marshall David & Friesen; Dwayne Thomas & Lyon; David Keith & McCray; Scott Baldwin & West; James Blair
  Assignee(s): Pfizer Inc.
  The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
  
  Patent expiration dates:
  
  
  • February 14, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
    ✓ 
    Drug product
  
  



• 
  Multiparticulate crystalline drug compositions having controlled release profiles
  Patent 7,887,844
  Issued: February 15, 2011
  Inventor(s): Appel; Leah E. & Ray; Roderick J. & Lyon; David K. & West; James B. & McCray; Scott B. & Crew; Marshall D. & Friesen; Dwayne T. & Herbig; Scott M. & Lo; Julian B.
  Assignee(s): Pfizer Inc.
  A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.
  
  Patent expiration dates:
  
  
  • February 14, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Zmax Extended-Release Oral Suspension Consumer Information (Wolters Kluwer)
• Zmax Consumer Information (Cerner Multum)
• Zmax Advanced Consumer Information (Micromedex)
• Azithromycin Consumer Information (Drugs.com)
• Azithromycin Consumer Information (Wolters Kluwer)
• Azithromycin Extended-Release Oral Suspension Consumer Information (Wolters Kluwer)
• Azithromycin Single-Dose Packet Consumer Information (Wolters Kluwer)
• Azithromycin Suspension Consumer Information (Wolters Kluwer)
• Azithromycin Tablets Consumer Information (Wolters Kluwer)
• Azithromycin Consumer Information (Cerner Multum)
• Azithromycin Advanced Consumer Information (Micromedex)
• Azithromycin Intravenous Advanced Consumer Information (Micromedex)
• Azithromycin AHFS DI Monographs (ASHP)

ActoPlus Met

See also: Generic ActoPlus Met XR

ActoPlus Met is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):

ACTOPLUS MET (metformin hydrochloride; pioglitazone hydrochloride - tablet; oral)

• 
  Manufacturer: TAKEDA GLOBAL
  
  Approval date: August 29, 2005
  
  Strength(s): 500MG;EQ 15MG BASE ^[AB], 850MG;EQ 15MG BASE ^[RLD][AB]

Has a generic version of ActoPlus Met been approved?

A generic version of ActoPlus Met has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ActoPlus Met and have been approved by the FDA:

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet; oral)

• 
  Manufacturer: MYLAN
  
  Approval date: February 25, 2011
  
  Strength(s): 500MG;EQ 15MG BASE ^[AB], 850MG;EQ 15MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition
  Patent 5,965,584
  Issued: October 12, 1999
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition
  Patent 6,166,042
  Issued: December 26, 2000
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  



• 
  Pharmaceutical composition
  Patent 6,166,043
  Issued: December 26, 2000
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  



• 
  Pharmaceutical composition
  Patent 6,172,090
  Issued: January 9, 2001
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  

See also...

• Actoplus Met Consumer Information (Drugs.com)
• Actoplus Met Consumer Information (Wolters Kluwer)
• Actoplus Met Consumer Information (Cerner Multum)
• Actoplus Met Advanced Consumer Information (Micromedex)
• Metformin Extended-Release/Pioglitazone Consumer Information (Wolters Kluwer)
• Metformin/Pioglitazone Consumer Information (Wolters Kluwer)
• Pioglitazone/Metformin Consumer Information (Wolters Kluwer)
• Pioglitazone/Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Metformin and pioglitazone Consumer Information (Cerner Multum)
• Metformin and pioglitazone Advanced Consumer Information (Micromedex)
• Pioglitazone and metformin Advanced Consumer Information (Micromedex)

Prolmon

Prolmon may be available in the countries listed below.

Ingredient matches for Prolmon

Protoporphyrin Disodium

Protoporphyrin Disodium is reported as an ingredient of Prolmon in the following countries:

• Japan

International Drug Name Search

Metronidazol Biomendi

Metronidazol Biomendi may be available in the countries listed below.

Ingredient matches for Metronidazol Biomendi

Metronidazole

Metronidazole is reported as an ingredient of Metronidazol Biomendi in the following countries:

• Spain

International Drug Name Search